Home

shutterstock_4370148971
shutterstock_4370148971
skiing
skiing
shutterstock_284522933
shutterstock_284522933
shutterstock_726743875
shutterstock_726743875
shutterstock_707244118
shutterstock_707244118
previous arrow
next arrow

BioTraxx. When You Need to Get It Right.

The rapid advancement of technologies such as next generation sequencing and CRISPR gene editing results in the continuous discovery of new kinase drug targets for many clinical conditions, including cancer and autoimmune diseases. 

Innovative solutions to address this clinical imperative is required as traditional kinase drug discovery and development approaches are not able to take advantage of this target-rich precision medicine opportunity.

We know that AI technologies will play a critical role in transforming the kinase drug discovery and development process. 

Learn how BioTraxx, an AI-enhanced in silico kinase drug discovery platform, can increase your success, save you time and reduce your cost.

Designing Better Medicines with Artificial Intelligence

PharmaSilico’s proprietary technology platform BioTraxx, an AI-enhanced in silico kinase drug discovery platform powered by the integration of deep learning, big data and the domain knowledge of the experts in the field, is designed to increase the efficiency of the pharmaceutical industry.

We can help you with your drug development programs.

Right Time. Right Patient. Right Drug.

No patient should go untreated. We are entering an era in which the scientific and clinical community can leverage the power of AI and big data to inform drug development programs and clinical decision making to improve outcomes. 

Now is the RIGHT TIME to identify the RIGHT PATIENT to treat with the RIGHT DRUG.

BioTraxx can help you develop the right kinase drug.

Imagine. Believe. Achieve.

Imagine a world in which every disease has an effective treatment. By leveraging the power of AI, our platform technology, BioTraxx, aims to discover safe and effective medications targeting by efficiently and intelligently evaluating millions of compounds against kinase drug targets in silico. 

Latest News.

Press Release: How Local Biotech Company Leverages its Deep Learning Platform to Identify Drugs to Treat COVID

Anthony Marotta3 November 20203 min read
Press Release: How Local Biotech Company Leverages its Deep Learning Platform to Identify Drugs to Treat COVID

VANCOUVER, November 3, 2020 / Pharmasilico, the AI-based drug discovery company, is pleased to announce that they have leveraged their proprietary AI platform to identify 22 candidate drugs that could be effective in combating the current global COVID-19 pandemic. Twelve…

4250 WESBROOK MALL VANCOUVER, BC CANADA V6T 1WT
© Pharmasilico

document.querySelectorAll('.skip-link-list').forEach(function(a) { a.remove() })